Ketti K. Terry

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

J. Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis et al. · Arthritis Research & Therapy · 2019 · 320 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.

Jeffrey R. Curtis, Hendrik Schulze‐Koops, Liza Takiya et al. · PubMed · 2017 · 69 citations

Medicine, Pharmacology, Pharmacotherapy +9

Development of a Physiologically Based Pharmacokinetic Model Describing 2-Methoxyacetic Acid Disposition in the Pregnant Mouse

Ketti K. Terry, Barbara A. Elswick, Frank Welsch et al. · Toxicology and Applied Pharmacology · 1995 · 50 citations

Pharmacy, Pharmacokinetics, Pharmacology +10

Developmental phase alters dosimetry‐teratogenicity relationship for 2‐methoxyethanol in CD‐1 Mice

Ketti K. Terry, Barbara A. Elswick, Donald B. Stedman et al. · Teratology · 1994 · 45 citations

Pharmacy, Pharmacology, Toxicology +17

SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years

J. Wollenhaupt, Joel C. Silverfield, E. B. Lee et al. · Annals of the Rheumatic Diseases · 2018 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15